When
Where
Online (Zoom)
Organizer
Navigating the German reimbursement landscape is one of the most common challenges we hear from Norwegian healthtech and digital health companies. The rules are complex; there are many actors to be aware of and getting the pathway wrong can cost years of market time. To cut through the complexity, we are bringing together two experts from the German system for a focused online session, and you are cordially invited to join and also bring your own questions.
In an interactive online setting, you will hear directly from an experienced reimbursement expert and a senior health insurance representative, and you can bring those questions that matter most to your company.
Gregor Jelen, Owner & Managing Partner | HEPICC GmbH
Gregor Jelen has 19 years of experience in the medical technology and healthcare industry, with a strong focus on market access and reimbursement in Germany. As founder of HEPICC GmbH, he works with startups, SMEs, medtech and pharma companies to build market access, reimbursement, and commercialization strategies for the German healthcare system, covering statutory and private health insurers as well as other key payers. His expertise spans product concept development, regulatory approval, clinical evidence, and the full pathway from innovation to reimbursable product. Talk Title: "Pathways to Reimbursement in Germany: From DiGA to Selective Agreements - an overview of market access and reimbursement options."
Speaker from AOK — to be confirmed Statutory Health Insurance Expert | AOK
We are in the process of confirming a speaker from AOK, the largest statutory health insurance network in Germany, covering over 27 million members. Their perspective will provide an inside view of how German health insurers assess new solutions, structure selective agreements, and make reimbursement decisions. These insights are applicable broadly across the statutory system, which covers approximately 90% of the German population.
• Get clarity on reimbursement pathways: and understand which route fits your solution
• Understand how selective agreements work in practice: what GKV funds look for, what are key parameters for success and how negotiations function
• Hear the insurer's perspective directly: criteria, timelines, and evidence standards that determine reimbursement decisions
• Ask your specific questions: submit them in advance for a structured expert dialogue, or ask live during open Q&A
The session opens with two short expert presentations, followed by a 30-minute expert dialogue and open Q&A. Both speakers stay on throughout, so the conversation can go where the questions take it.
To make the most of the expert time, we will collect your questions in advance. When you register, please share the one question or topic most relevant to your company. We will share these with our speakers prior to the event, allowing them to structure the presentation and dialogue around the themes that matter most to the group. The session will be moderated by Jutta Heix, Oslo Cancer Cluster.
This session is designed for Norwegian companies in digital health, healthtech, diagnostics, and medtech that are actively entering or planning to enter the German market, with a particular focus on companies seeking reimbursement or exploring selective agreements with German health insurers. We particularly welcome our export "landslag" companies as well as companies at an earlier stage of German market preparation.